Previous 10 | Next 10 |
home / stock / ocul / ocul articles
U.S. stock futures were higher this morning, with the Dow futures gaining over 100 points on Monday. Shares of BioNTech SE (NASDAQ:BNTX) fell sharp...
BEDFORD, Mass., May 06, 2024 (GLOBE NEWSWIRE) -- Ocular Therapeutix, Inc. (NASDAQ:OCUL, "Ocular", the "Company")), a biopharmaceutical company c...
BEDFORD, Mass., May 03, 2024 (GLOBE NEWSWIRE) -- Ocular Therapeutix, Inc. (NASDAQ:OCUL, "Ocular", the "Company")), a biopharmaceutical company ...
Shares of Super Micro Computer, Inc. (NASDAQ:SMCI) fell sharply during Friday's session. The company announced its third-quarter earnings date...
On Thursday, Ocular Therapeutix Inc (NASDAQ:OCUL) announced topline results from the Phase 1 HELIOS study evaluating Axpaxli versus sham ...
Shares of Las Vegas Sands Corp. (NYSE:LVS) fell sharply during Thursday's session despite better-than-expected first-quarter results. The comp...
Nadia K. Waheed, MD, MPH, Appointed Chief Medical Officer; Peter K. Kaiser, MD, to Become Chief Development Officer; Andrea Gibson, PhD, Named Vi...
BEDFORD, Mass., April 15, 2024 (GLOBE NEWSWIRE) -- Ocular Therapeutix, Inc. (NASDAQ:OCUL) ("Ocular"), a biopharmaceutical company committed to e...
Phase 2 data highlight consistent and sustained reductions in Intraocular Pressure (IOP), statistically significant (p<0.0001) through six mont...
News, Short Squeeze, Breakout and More Instantly...
Ocular Therapeutix Inc. Company Name:
OCUL Stock Symbol:
NASDAQ Market:
Ocular Therapeutix Inc. Website:
2024-06-27 18:00:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
151 subjects enrolled in various stages of loading and randomization in SOL-1 pivotal study of AXPAXLI in wet AMD as of June 7, 2024 Announces plans for SOL-R study to evaluate repeat doses of AXPAXLI in wet AMD 48-week HELIOS NPDR results show 23.1% of patients in AXPAXLI arm e...
2024-06-07 11:52:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...